Novo Nordisk faces a shifting landscape in the weight-loss drug market as rival Eli Lilly gains ground with more effective treatments like Zepbound. The company, once the undisputed leader with Ozempic and Wegovy, is pivoting its strategy to address the "curse of the leader" by focusing on health outcomes beyond mere weight loss, such as cardiovascular and kidney health. The CEO emphasizes the importance of evolving from a traditional diabetes-focused pharmaceutical model to one that treats obesity patients as consumers, necessitating new e-health distribution channels. Despite recent setbacks in clinical trials for the next-generation drug CagriSema, the company is prioritizing its successful oral Wegovy pill and a robust pipeline of future treatments, including the triple-agonist UBT251. By slashing U.S. list prices, the firm aims to balance mass-market accessibility with the high margins required for continued innovation in a highly competitive, fast-paced industry.
Sign in to continue reading, translating and more.
Open full episode in Podwise